🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

PRP vs PRP+Betamethasone vs Betamethasone Injection for Upper Trapezius Myofascial Pain

RecruitingPhase 4Ages 18 Years - 65 YearsAllUniversity of Kyrenia
NCT07547605 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Brief Summary Myofascial pain syndrome (MPS) is a common musculoskeletal condition characterized by active trigger points (TrPs), which are hypersensitive, painful nodules within taut bands of skeletal muscle. The upper trapezius muscle is one of the most frequently affected sites. Trigger point injection (TPI) is a widely used minimally invasive treatment for patients who are refractory to conservative management. Corticosteroids provide rapid anti-inflammatory effects, whereas platelet-rich plasma (PRP) has regenerative properties through growth factors that may support tissue healing. Despite their widespread use, the optimal injectate for TPI remains unclear. Additionally, the potential benefit of combining PRP with corticosteroids has not been adequately studied in upper trapezius MPS. This study is a single-center, prospective, randomized, assessor-blinded controlled trial desig

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age between 18 and 65 years * Presentation to the Orthopedics and Traumatology outpatient clinic with neck and/or shoulder pain * Diagnosis of upper trapezius myofascial pain syndrome based on Simons and Travell criteria, including: * Presence of a taut band * Local tenderness * Referred pain pattern * Local twitch response * Presence of a single active trigger point in the upper trapezius muscle * Symptom duration ≥ 4 weeks * Pain intensity ≥ 4 on the visual analog scale (VAS) * Inadequate response to at least 4 weeks of conservative treatment (physical therapy and/or oral analgesics) * Ability to provide written informed consent Exclusion Criteria: * Presence of multiple active trigger points * Diagnosis of fibromyalgia according to ACR 2010 criteria * Cervical radiculopathy or myelopathy * Trigger point injection in the same region within the past 3 months * Coagulopathy or current anticoagulant or antiplatelet therapy * Known allergy or contraindication to corticosteroids, local anesthetics, or PRP components * Active infection (systemic or local) * Pregnancy or lactation * Thrombocytopenia (platelet count \< 100,000/µL) * Malignancy * Inability to cooperate or provide informed consent
💊

What it tests

  • Autologous Platelet-Rich Plasma (PRP)
  • PRP plus Betamethasone
  • Betamethasone (Diprospan)
📍

Where

2 sites
Dr. Suat Gunsel University of Kyrenia Hospital
Kyrenia, Cyprus
Dr. Suat Gunsel University of Kyrenia Hospital
Kyrenia, Cyprus
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy